A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new pill to see if it is safe for adults with multiple myeloma that has come back or not responded to treatment. The pill stops a process that helps the cancer grow.
Scientists are testing a new pill to see if it is safe for adults with multiple myeloma that has come back or not responded to treatment. The pill stops a process that helps the cancer grow.
*Third Opinion AI Generated Synopsis
Trial Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: